Profitability problems continue at Molnlycke:
This article was originally published in Clinica
Executive Summary
Sharp rises in fibre costs caused operating profits at Molnlycke to fall 21% to SKr 203 million ($27 million) in the first three months of 1995. Part of the Swedish pulp, paper and packaging group SCA, Molnlycke saw sales rise 25% to SKr 4,155 million during the same period. SCA's hygiene products division (of which Molnlycke is a part) recorded 12% growth for incontinence care products, while sales of clinical products increased 8%.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.